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Abstract 
Objective 
We sought to develop a simulation modelling method to help better understand the complex 
interplay of factors that lead to people with Type 2 diabetes and asthma not taking all of their 
medication as prescribed when faced with multiple medications (polypharmacy). 
Research Design and Methods 
In collaboration with polypharmacy patients, GPs, pharmacists and polypharmacy 
researchers, we developed a map of factors that directly and indirectly affect somebody’s 
decision to take their medication as prescribed when faced with multiple Type 2 diabetes and 
asthma medications.  We then translated these behavioural influences into logical rules using 
data from the literature and developed a proof-of-concept Agent Based Simulation model that 
captures the medicine taking behaviours of those with Type 2 diabetes and asthma taking 
multiple medications, and which predicts both the clinical effectiveness and rates of 
adherence for different combinations of medications. 
Conclusions 
The model we have developed could be used as a prescription support tool or a way of 
estimating medicine taking behaviour in cost-effectiveness analyses. 
  
 
 
 
 
 
 
 
 
 
 
What this paper adds 
What is already known on this subject 
 A significant number of people who are prescribed multiple medications do not take all of 
their medications as prescribed. 
 Prescribed medication not being taken can lead to risks for patients as well as wasted costs 
for the NHS, and increased access to health services as people fall ill. 
 The reasons why people do not take their medication as prescribed are numerous and 
complex. 
What this study adds 
 We have developed a proof-of-concept simulation tool to capture the complex behavioural 
dynamics leading to people with both type 2 diabetes and asthma not taking their 
medication as prescribed. 
 The tool can be used to predict the likely medication adherence, clinical wellbeing and 
treatment burden of different prescription combinations for these conditions. 
 The tool could be easily extended to incorporate other combinations of conditions that 
lead to multiple medications being prescribed. 
Introduction 
Polypharmacy, in which people are prescribed multiple medications (commonly for multiple 
comorbidities) [1] is growing [2-4], particularly as we face an ageing population developing 
multiple conditions [5].  Polypharmacy can be problematic because of the consequent 
treatment burden, safety issues and because a significant number of people who are 
prescribed multiple medications do not take all of their medication [6].  This can lead to 
wasted costs from unused medication [7] and the resource and cost burden of patients 
accessing health services that might result from sub-optimal control of their conditions [8]. 
However in some situations, non-adherence can lead to fewer adverse drug reactions [9].  
For many years, there has been a focus on increasing “adherence” (formerly termed 
“compliance”) within such populations [10].  Many studies have examined the potential 
factors that might lead to people not adhering to their prescription [11], although often such 
studies have focused on single factors or small subsets. Other studies have been concerned 
with understanding how people manage their medicines in the context of their everyday lives 
[12]. In a synthesis of qualitative research, Pound et al [13] found considerable reluctance to 
take medicine and a preference to take as little as possible. Recognising the problem of 
treatment burden, May and colleagues [14] have coined the term ‘minimally disruptive 
medicine’ to guide the search for less burdensome clinical practice. 
Agent Based Simulation (ABS) is a simulation modelling method that allows for the 
modelling of behavioural and motivational aspects within a system, and uses such individual-
level behaviours as the building blocks for the model, allowing population-level dynamics to 
emerge as properties of individual behaviours and interactions [15].  Agent Based Simulation 
has a rich heritage of being used in this way in ecology [16], but has less often been applied 
to human systems [17].  However, there is a developing interest in applying Agent Based 
Simulation to model health and social care systems in which the behaviours of individuals 
within that system are the focus or an integral component [17-22]. 
In this paper, we present a novel and innovative proof-of-concept model, developed in 
collaboration with people experiencing polypharmacy, health professionals and 
polypharmacy researchers, to demonstrate the potential of Agent Based Modelling to better 
understand medicine taking behaviour in the context of polypharmacy for those with both 
type 2 diabetes and asthma.  We describe the development of the model, how the model 
works, and its potential further development to be used as a tool for supporting polypharmacy 
prescribing policy. 
Research Design and Methods 
The Software 
The model described in this paper was built using AnyLogic University 6.7.1 (© The 
Anylogic Company, http://www.anylogic.com/).   
The Working Group 
The project working group included two operational researchers, two polypharmacy 
researchers, two patients taking multiple medications from the local patient involvement 
group (PenPIG), two pharmacists (one of whom is also a representative for the local 
Academic Health Science Network) and a General Practitioner. 
Population of Interest 
People with both type 2 diabetes and asthma represent a growing sub-population [23], who 
have to manage two very different conditions where treatment burden may be high because of 
potential conflicts between medications [24].  Therefore, we selected our population of 
interest in this model as those with both (and only) type 2 diabetes and asthma, although the 
modelling approach used here could be applied to other sub-populations.  
Mapping the Behavioural System 
A key step when designing and developing any model is to gain an understanding of the 
system to be modelled [25].    In this project, we sought to understand the behavioural logic 
associated with the taking of prescribed medications.  Therefore, we developed a map of 
potential factors that might directly or indirectly affect the medicine taking behaviour of 
someone with type 2 diabetes and asthma.  This map was developed collaboratively within 
the working group, drawing on the expertise of people taking multiple medications, 
researchers and prescribers, and exploring the significant body of literature in this area.  
Literature search strategies were strategic, and looked for combinations of terms for the 
conditions of interest and literature concerning medication that included broad terms of 
“burden of treatment”, “patient experiences” and “adherence”.  Specific searches were also 
undertaken that looked for special factors of interest, such as “needle anxiety”, “supply of 
medication” and “storage of medication”.  We also included studies of multimorbidity that 
featured one or more of the conditions of interest, and included both qualitative and 
quantitative studies.  A total of 164 relationships were identified using an iterative process. 
Identifying Relationships to Model 
We assume that our population of interest does not include pregnant women or children, as 
medicine taking amongst these sub-populations is more complex [26, 27].  For this initial 
prototype, we assume that the prescribed combination of medications represents the complete 
set of medications available to patients in that simulation, and therefore we did not need to 
consider the impact of someone’s willingness to try new medications, or how that might be 
affected by their desire to be in control of their condition, their personal goals or their desire 
to feel better.  Also, we did not need to model the impact of the patient having conditions 
other than type 2 diabetes and asthma, as we assume our population has both and only these 
two conditions.  As diabetes and asthma medications are not considered to be either addictive 
or analgesic in nature (local pharmacist opinion), we did not need to consider how the 
addictive properties of medication or whether or not the medication provides pain relief 
would impact medicine taking. Our pharmacists considered that such medications were less 
likely to lose effectiveness over time (although obviously the severity of the conditions could 
worsen over time).  We also assumed that medication supply problems were unlikely for 
common conditions such as diabetes and asthma.  Finally, in order to ensure we were 
modelling individual behaviours associated with medicine taking, we assumed that our 
population was able to make their own decisions about their medications, and therefore we 
did not consider the impact of cognitive impairment or the need for assistance taking 
medications.  After eliminating these factors, we were left with 142 influencing relationships 
to model (Appendix A). 
Once we had identified those influencing factors that were not relevant to our modelled 
population, we explored the literature to identify potential quantitative and qualitative data 
that could be used to represent the remaining factors within the model.  Principally, we were 
looking for data that could be translated into behavioural ‘rules of thumb’, either via 
quantitative data from which probabilities of behaviour could be inferred, or qualitative data 
from which we could infer categorical data and relationships.  As part of this process, for 
some relationships we found evidence that they were untrue, and for others we were unable to 
find usable data.  In all, we were left with 70 relationships to be included in the model. 
Due to the timeframe of the project, we were unable to include real medication data in the 
prototype model, and instead opted to develop the tool such that users could input such drug 
data by specifying the probability of condition progression and improvement for each 
medication.  Consequently, some of the medication and condition severity related factors are 
not explicitly captured in the prototype.  This left us with a final total of 59 relationships that 
were modelled.  Full details of the relationships that were included and excluded, and the 
reasons for exclusion, are detailed in Appendix A. 
Translating the Behavioural System into Behavioural Rules 
For the 59 relationships to be included in the model, we needed to translate the quantitative 
and qualitative data found in the literature into behavioural rules that could be implemented 
in the model.  Typically, these rules translated the data into “IF THEN” statements that would 
determine the ‘state’ of certain influencing factors.  For example, we found evidence to show 
that if someone’s perception of the severity of their condition is low, there is a 22% increased 
probability of non-adherence [28].  In the model, we translated this into a rule that states that 
if an agent’s perception of their state of health is less than or equal to 50%, the “proposed 
action” from this influencing relationship would be to adhere only 78% of the time.  
Appendix B details the full set of behavioural rules for each influencing factor modelled. 
Evidence shows that the impact of perceived state of health has twice the impact on 
adherence as any other factor that might influence medicine taking behaviour [29].  
Therefore, in the model we split the behavioural influences into two categories – “Wellness 
Factors” which represent the influence of someone’s state of health, how well they feel, and 
the effects of the drugs they are taking, and “General Factors” which represent everything 
else.  We configured the model so that the “Wellness Factors” influenced behaviour twice as 
often as the “General Factors”. 
The influence of someone’s state of health on their medicine taking can be thought to be 
comprised of two central components – how well they actually are / the effects of their 
medication and their perception of how well they are / the effects of their medication [28].  
Such concepts can also be found in the Health Belief Model [30].  Perceptions of state of 
health will change over time.  To capture these elements, we used a Linear Operator Learning 
Rule within a Reinforcement Learning framework [31], which is a commonly used approach 
to describe reinforcement behaviours in ecological modelling [32].  Reinforcement Learning 
describes a learning in which actions that are more rewarding are increasingly taken, whilst 
actions that offer less reward (or punishment) are gradually avoided.  In the context of 
medicine taking, this represents the way in which people will tend to take medications based 
on their beliefs about the effects the medication is having and their experience taking the 
medication [33]. 
Specifically, each person in the model maintains a perception of how well each combination 
of drugs makes them feel.  If they have yet to experience a drug combination, we assume that 
they perceive that combination of drugs to be no better or worse than any other combination 
they have yet to try.  For each simulated day in the model, each person updates their 
perception of the combination of drugs they are currently taking using the following Linear 
Operator Learning Rule : 
wt = Wtsα + (1-α)wt-1 
where wt is the person’s perception of their state of health at time t, Wt is the person’s actual 
state of health at time t, s is their sensitivity to their true state of health (ranging from 0 
representing complete insensitivity to 1 representing full awareness of true state of health), α 
represents how much their medicine taking is weighted in favour of how they currently feel 
compared to how they felt previously (ranging from 0 for people who do not update their 
perceptions based on new information to 1 for people who only consider new information), 
and wt-1 is the person’s previous perception of their state of health taking this drug 
combination. 
After a person in the model has updated their perception of their health state, they will 
compare it to their perceptions about how well they felt taking the other drug combinations.  
A threshold T is given by the “perceived wellness” value of previously sampled medication 
combinations.  If the person’s perception of their current health falls a given percentage 
below the threshold T, the proposed action from the “Wellness Factors” will be to not take 
their medication.  The person may then switch to the combination of medications that they 
perceive to make them feel most “well”.  However, this may not be the action that is taken, as 
people are not just influenced by “Wellness Factors”. 
In addition, each “General Factor” resolves to a binary value of “Take” or “Don’t Take” via 
the behavioural rules translated from the data, which represents the “proposed action” from 
that influencing factor.  At the end of each simulated day, a proposed action will be selected 
at random from each person’s set of factors (both “General Factors” and “Wellness Factors”).  
The probability of selecting any action is determined by its weighting.  In the prototype 
model, the probability of choosing the proposed action from the “Wellness Factors” is 67%, 
compared to 33% for the “General Factors” [29].  In the absence of data, we assume that all 
“General Factors” have equal weighting. 
If the selected proposed action is “Take”, then no action will be taken.  Otherwise, if the 
selected proposed action is from the “Wellness Factors”, then the person in the model will 
switch to the proposed alternative drug combination that they perceive to make them feel 
most “well”.  If the selected proposed action is from a “General Factor”, then the person will 
either switch to their perceived best alternative or select a drug combination at random if the 
influence from how well they feel says they should take their medication. 
Figure 1 provides an overview of how the behaviour in the model works. 
States of health 
Each person in the model is in two states at any one time – one representing their type 2 
diabetes state of health, and one representing their asthma state of health.  These represent the 
true states of health for each person in the model.  For simplicity, we use three states of health 
for each condition in the prototype model, emulating the three most common stages of 
treatment for each condition [34, 35].  The true state of health value is calculated as the sum 
of the health values assigned to each state from each condition, with a Stage 1 (least severe) 
state of health assigned a value of 50%, a Stage 2 state of health assigned a value of 25%, and 
a Stage 3 state of health (most severe) assigned a value of 0%.  Therefore, the true overall 
state of health of any person in the model can range between 0% (most severe state of health 
for both conditions) to 100% (least severe state of health for both conditions). 
Medication Effects 
Medication effects are specified in the model for each possible combination of medication.  
In the prototype, there are four prescribed medications – two for asthma, and two for 
diabetes.  People with both Type 2 diabetes and asthma may take up to three to four different 
medications, depending on the stages of their conditions [34, 35].  The effects of the drugs for 
each combination are specified by the user of the model in terms of the probability per day of 
a transition between health states for each condition.  This allows users to specify the 
effectiveness of each combination of medications for each condition. 
Outputs 
Whilst running, the model reports  adherence and wellness levels within the population  over 
time.  Users of the model are also able to access the details of any given person within the 
population.  These details include their current state of health and perceived state of health, 
the severity of their conditions, the medicine taking decision they are currently making and 
the factors that influenced that decision, and parameter values relevant to the various factors 
that influence medicine taking. 
Conclusions 
The intention of building this model was for it to serve as a proof-of-concept to demonstrate 
how the medicine taking behaviours of those taking multiple medications for both type 2 
diabetes and asthma could be simulated, and how such a model could be used to provide 
evidence to inform prescribing practice.  We have shown how such behaviours can be 
translated from qualitative and quantitative data in the literature into behavioural rules that 
can be used in an Agent Based Simulation, and how the effect of state of health and 
medication effectiveness on medicine taking decisions can be simulated using Reinforcement 
Learning and a Linear Operator Learning Rule.  We have also shown how adherence rates 
and states of health across the simulated population can be calculated and reported, which, 
along with the level of treatment burden, are likely to be key outcome measures when 
comparing medication combinations to inform prescribing practice. 
The principal way in which this model could be used is to compare combinations of 
medication prescribed for those with type 2 diabetes and asthma, not only in terms of their 
clinical effectiveness but also the likely treatment burden and adherence to this prescription 
within a given population.  However, the modelling method could be applied to any 
combination of conditions where people are taking multiple and perhaps conflicting 
medications.  The evidence generated by a model such as we’ve described would allow trade-
off decisions to be made – for example, a particular combination of medications may have a 
slightly lower clinical effectiveness but result in fewer side effects or a much higher level of 
adherence, helping to inform a decision about whether to accept a trade-off in clinical 
effectiveness in return for more people taking more of their medication as prescribed.  These 
decisions could be made by the prescriber (such as a General Practitioner) with individual 
patients using a simulation ‘population’ reflecting the patient in question, or on a larger scale 
in terms of informing prescribing policy locally or nationally.  Comparisons in terms of 
treatment burden (how burdensome a treatment or combination of treatments is to follow) 
could be made externally to the model using expert judgement, or internally if the model 
were extended to incorporate influencing factors such as complexity, frequency and 
flexibility of the treatment regimen, adverse drug reactions, complexity and portability of the 
format of delivery of the medications, and total number of medications prescribed.  We 
already include the influence of the level of interference with daily life, which is likely an 
important aspect of treatment burden [36], and this could be extended to reflect specific 
medication regimens. 
There is also potential for this model to be used to enhance traditional cost-effectiveness 
analyses.  Such analyses seek to determine the cost-effectiveness of an intervention (often a 
new treatment) in terms of its incremental benefits and costs compared with an existing 
intervention for a given sub-population [37].  Some cost-effectiveness studies have started to 
incorporate simple estimates of adherence [38], acknowledging the potential impact of 
adherence on the cost-effectiveness of an intervention [39].  However, such studies typically 
use poor or invalid methods to incorporate concepts of adherence [40].  Our model could be 
used as a means of better estimating adherence rates for the studied population, either directly 
if the population was those with type 2 diabetes and asthma, or with extension to the model 
for other sub-populations.  Alternatively, the model could be extended to incorporate the 
cost-effectiveness elements, as we already allow the user to specify transition probabilities 
between health states with different drug combinations, and we assign quantifications of 
‘wellness’ to each combination of drug states which could easily be used to represent Quality 
Adjusted Life Years (QALYs) [41].  If the model were extended to also assign costs to each 
combination of states, the cost-effectiveness analysis could be conducted solely using this 
simulation model, with the added benefit of a more sophisticated intrinsic means of 
considering medicine taking behaviours. 
To our knowledge, the method of simulating medicine taking behaviours that we have 
outlined in this paper has not been developed before, and therefore presents an innovative and 
exciting opportunity to model systems in health and social care where the medicine taking 
behaviours of people within those systems is a non-trivial component.  Furthermore, beyond 
medicine taking in polypharmacy, there is an increasing acknowledgement that many 
healthcare systems are significantly dependent upon the behaviour of the ‘actors’ within that 
system.  Clearly, the model would need to be validated against relevant data sets before being 
applied in any of the ways we have proposed in this paper, but we feel strongly that the 
modelling approach we have outlined could be a vital tool to help to better understand the 
complex interplay of factors that lead to people who are prescribed multiple medications not 
taking all of their medication as prescribed. 
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Figure 1.  Overview of the behavioural logic of the model for each person at each time step.  
Indirect general factors influence direct general factors, which resolve to a binary proposed 
action to take the medicine or not to take it.  The wellness factor also resolves to a proposed 
action, depending on the person’s perception of their state of health with their current drug 
combination.  Proposed actions are selected at random according to the weighting attributed 
to them, and the person will either switch their medication or continue as they are depending 
on the selected action. 
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Appendix A 
Relationship 
# 
Influencing Factor 
 
(FROM) 
Factor Being Influenced 
(TO) 
Included in 
Model? 
Reason for Exclusion (if applicable) 
1 Affordability of medications to 
patient 
Adherence YES  
2 Household income / financial 
status 
Affordability of medications to 
patient 
NO Not needed as socio-economic status specified 
directly by the user when setting up model 
3 Household income / financial 
status 
Health literacy NO No data 
4 Level of education Health literacy YES  
5 Ethnicity Adherence NO (Osborn, Cavanaugh et al. 2011) found that it is 
health literacy that explains disparities in diabetes 
medication adherence, not ethnicity itself 
6 Ethnicity Health literacy NO Not needed as health literacy specified directly by 
user 
7 Ethnicity Language barriers NO Not needed as language barriers specified directly 
by user 
8 Language barriers Frequency of interaction with 
health professionals 
YES  
9 Language barriers Health literacy YES  
10 Health literacy Frequency of research of 
information on the internet 
YES  
11 Frequency of research of 
information on the internet 
Health literacy NO It is the opposite relationship that is true (health 
literacy influences frequency of research of 
information on the internet) (see relationship 10) 
(Neuberger 2000, Wald, Dube et al. 2007, Sarkar, 
Karter et al. 2010) 
12 Health literacy Awareness of severity and / or 
nature of condition 
NO Not needed as user directly specifies level of 
understanding of necessity of treatment 
13 Health literacy Awareness of why prescribed NO Not needed as user directly specifies level of 
medications understanding of necessity of treatment 
14 Health literacy Adherence to recommended 
lifestyle changes 
NO We don’t use real progression data in the 
prototype, so unable to capture this 
15 Preference to use non-drug 
alternatives (diet etc) 
Adherence YES  
16 Pregnancy Adherence NO We assume our population does not contain 
pregnant women 
17 Support in workplace / place of 
education to take medication 
Adherence YES  
18 Support in workplace / place of 
education to take medication 
Openness about condition YES  
19 Openness about condition Adherence YES  
20 Desire to feel “normal” by not 
having to take medication 
Adherence YES  
21 Desire to feel “normal” by not 
having to take medication 
Openness about condition YES  
22 Willingness to try new 
medications 
Adherence NO We assume that the prescribed combination of 
drugs in the model represents the complete set of 
drugs available 
23 Willingness to try new 
medications 
Desire to be “in control” of self / 
condition 
NO We assume that the prescribed combination of 
drugs in the model represents the complete set of 
drugs available 
24 Desperation to feel better Willingness to try new medications NO We assume that the prescribed combination of 
drugs in the model represents the complete set of 
drugs available 
25 Desire to be “in control” of self / 
condition 
Adherence YES  
26 Desire to be “in control” of self / 
condition 
Willingness to try new medications NO We assume that the prescribed combination of 
drugs in the model represents the complete set of 
drugs available 
27 Personal goals Willingness to try new medications NO We assume that the prescribed combination of 
drugs in the model represents the complete set of 
drugs available 
28 Personal goals Desire to be “in control” of self / 
condition 
NO No data 
29 Life events Adherence YES  
30 Stress Adherence NO Covered under Life Events 
31 Needle anxiety Adherence YES  
32 Presence of other conditions that 
may affect ability to take 
medications 
Adherence NO We assume our population has both and only Type 
2 Diabetes and asthma 
33 Gender Adherence YES  
34 Alcohol abuse, illicit drug use and 
smoking status 
Adherence YES  
35 Addictive properties of medication Adherence NO Diabetes and asthma medications do not tend to be 
addictive in nature 
36 Whether medication provides 
pain relief 
Adherence NO Diabetes and asthma medications do not tend to be 
analgesic in nature 
37 Severity of condition Adherence YES  
38 Severity of condition Desperation to feel better NO Desperation to feel better only influences 
willingness to try new medications in our map, and 
is therefore not required because we are not 
modelling a willingness to try new medications 
39 Time since onset Severity of condition YES  
40 Time since diagnosis Acceptance of diagnosis YES  
41 Acceptance of diagnosis Adherence YES  
42 Prioritisation of condition and 
treatment regimen 
Adherence NO No data 
43 Prioritisation of condition and 
treatment regimen 
Adherence to recommended 
lifestyle changes 
NO No data 
44 Severity of condition Prioritisation of condition and 
treatment regimen 
NO No data 
45 Adherence to recommended 
lifestyle changes 
Severity of condition NO We don’t use real disease progression data in the 
prototype, so unable to capture this 
46 Reduced efficacy of drugs over Adherence NO Diabetes and asthma medications unlikely to lose 
time effectiveness over time (although severity of 
condition could worsen over time) 
47 Time since diagnosis Adherence YES  
48 Time since diagnosis Reduced efficacy of drugs over time NO Diabetes and asthma medications unlikely to lose 
effectiveness over time (although severity of 
condition could worsen over time) 
49 Time since diagnosis Severity of condition NO It is the time since onset that would influence 
condition severity, not time since diagnosis (see 
relationship 39) 
50 Severity of condition Total number of drugs prescribed NO Total number of drugs prescribed fixed at four in 
prototype 
51 Total number of drugs prescribed Adherence NO Total number of drugs prescribed fixed at four in 
prototype 
52 Severity of condition Complexity and portability of 
format of delivery of drugs 
NO No real drug data used in prototype 
53 Complexity and portability of 
format of delivery of drugs 
Adherence NO No real drug data used in prototype 
54 Severity of condition Complexity and frequency of 
treatment regimen 
NO No real drug data used in prototype 
55 Complexity and frequency of 
treatment regimen 
Adherence NO No real drug data used in prototype 
56 Severity of condition Flexibility of treatment regimen NO No real drug data used in prototype 
57 Flexibility of treatment regimen Adherence NO No real drug data used in prototype 
58 Severity of condition Frequency of interaction with 
health professionals 
NO No data 
59 Time since diagnosis Level of interference with daily life NO No data 
60 Level of interference with daily life Adherence YES  
61 Age Adherence YES  
62 Age Level of interference with daily life NO No data 
63 Age Cognitive impairment NO We assume our population is able to make their 
own decisions about their medication 
64 Cognitive impairment Adherence NO We assume our population is able to make their 
own decisions about their medication 
65 Age Deference YES  
66 Deference Adherence YES  
67 Relationship with / trust in health 
professionals 
Awareness of severity and / or 
nature of condition 
NO Not needed as user directly specifies level of 
understanding of necessity of treatment 
68 Awareness of severity and / or 
nature of condition 
Adherence YES  
69 Relationship with / trust in health 
professionals 
Undertaking a Medicine Use 
Review (MUR) 
NO No data 
70 Undertaking a Medicine Use 
Review (MUR) 
Adherence NO No data 
71 Relationship with / trust in health 
professionals 
Deference NO No data 
72 Relationship with / trust in health 
professionals 
Awareness of why prescribed 
medications 
NO Not needed as user directly specifies level of 
understanding of necessity of treatment 
73 Awareness of why prescribed 
medications 
Adherence NO No data, and considered similar enough to 
“Awareness of severity and / or nature of 
condition” 
74 Stigma of taking medication in 
public (e.g. injections) 
Adherence YES  
75 Influence of health professionals 
to promote adherence 
Adherence YES  
76 Concerns about potential long 
term effects 
Adherence YES  
77 Adverse interactions with other 
drugs (POM and OTC) 
Adherence NO We assume no drugs other than those prescribed 
are available to the patient (and those interactions 
would be captured in the user-specified transition 
probabilities) 
78 Difficulties obtaining timely repeat 
prescriptions 
Adherence YES  
79 Concerns about medication 
supplies 
Adherence NO We assume there would not be supply problems for 
diabetes and asthma medication 
80 Lack of space to store medications 
at home 
Adherence NO We did not feel this would be problematic for 
diabetes and asthma medications 
81 Level of shared decision making 
about treatment 
Adherence NO No data 
82 Dislike of taking medications Adherence YES  
83 Need for assistance Adherence NO We assume our population is able to make their 
own decisions about their medication 
84 Level of patient agreement with 
treatment plan 
Adherence NO No data 
85 Perceived adverse effects Adherence YES  
86 Perceived benefits Adherence YES  
87 Perceived “wellness” Adherence YES  
88 Influence of information found on 
the internet 
Adherence YES  
89 Influence of the media Adherence NO No data 
90 Influence of family, friends and 
carers (social connectivity) 
Adherence YES  
91 Receiving shock / sudden 
degradation of health 
Adherence NO No data 
92 Frequency of interaction with 
health professionals 
Awareness of why prescribed 
medications 
NO No data 
93 Frequency of interaction with 
health professionals 
Awareness of severity and / or 
nature of condition 
NO No data 
94 Relationship with / trust in health 
professionals 
Influence of health professionals to 
promote adherence 
YES  
95 Relationship with / trust in health 
professionals 
Frequency of research of 
information on the internet 
YES  
96 Relationship with / trust in health 
professionals 
Level of shared decision making 
about treatment 
NO No data 
97 Frequency of interaction with 
health professionals 
Relationship with / trust in health 
professionals 
NO No data 
98 Frequency of research of Influence of information found on YES  
information on the internet the internet 
99 Influence of information found on 
the internet 
Expectations of drug benefits NO No data 
100 Influence of information found on 
the internet 
Expectations of drug adverse 
effects 
NO No data 
101 Need for assistance Influence of family, friends and 
carers (social connectivity) 
NO We assume our population is able to make their 
own decisions about their medication 
102 Living alone Influence of family, friends and 
carers (social connectivity) 
NO Already captured in data used for relationship 90 
103 Level of shared decision making 
about treatment 
Level of patient agreement with 
treatment plan 
NO No data 
104 Frequency of interaction with 
health professionals 
Level of shared decision making 
about treatment 
NO No data 
105 Frequency of interaction with 
health professionals 
Influence of health professionals to 
promote adherence 
YES  
106 Reluctance to consult with 
professionals for fear of “wasting 
their time” 
Frequency of interaction with 
health professionals 
YES  
107 Time since diagnosis Experience of taking similar / 
equivalent medication 
NO No data 
108 Access to transport Access to health professionals NO No data 
109 Access to health professionals Frequency of interaction with 
health professionals 
NO No data 
110 Access to health professionals Difficulties obtaining timely repeat 
prescriptions 
NO No data 
111 Frequency of interaction with 
health professionals 
Information received from health 
professionals 
NO No data 
112 Medication supply problems Concerns about medication 
supplies 
NO We assume there would not be supply problems for 
diabetes and asthma medication 
113 Medication supply problems Difficulties obtaining timely repeat 
prescriptions 
NO We assume there would not be supply problems for 
diabetes and asthma medication 
114 Difficulties obtaining timely repeat Concerns about medication NO We assume there would not be supply problems for 
prescriptions supplies diabetes and asthma medication 
115 Availability of convenient 
prescription services 
Difficulties obtaining timely repeat 
prescriptions 
NO No data 
116 Level of prescription record 
sharing 
Adverse interactions with other 
drugs (POM and OTC) 
NO We assume no drugs other than those prescribed 
are available to the patient (and those interactions 
would be captured in the user-specified transition 
probabilities) 
117 Lifestyle / work patterns Level of interference with daily life NO No data 
118 Concerns about potential long 
term effects 
Dislike of taking medications NO No data 
119 Perceived adverse effects Concerns about potential long term 
effects 
YES  
120 Perceived adverse effects Expectations of drug adverse 
effects 
YES  
121 Perceived adverse effects Perceived “wellness” YES  
122 Sensitivity to drug adverse effects Perceived adverse effects YES  
123 True adverse effects Perceived adverse effects YES  
124 True adverse effects Sensitivity to drug adverse effects NO We do not include real drug data, and therefore 
assume sensitivity to drug effects to be constant 
over the duration of the simulation 
125 True adverse effects True “wellness” YES  
126 Expectations of drug adverse 
effects 
Sensitivity to drug adverse effects NO We do not include real drug data, and therefore 
assume sensitivity to drug effects to be constant 
over the duration of the simulation 
127 Perception of the adverse effects 
experienced by others taking 
medication 
Sensitivity to drug adverse effects NO We do not include real drug data, and therefore 
assume sensitivity to drug effects to be constant 
over the duration of the simulation 
128 True adverse effects experienced 
by others taking the medication 
Perception of the adverse effects 
experienced by others taking 
medication 
NO No data 
129 Level of contact with others with 
condition 
Perception of the adverse effects 
experienced by others taking 
NO No data 
medication 
130 Level of contact with others with 
condition 
Perception of the benefits 
experienced by others taking 
medication 
NO No data 
131 True clinical benefits experienced 
by others taking the medication 
Perception of the benefits 
experienced by others taking 
medication 
NO No data 
132 Perception of the benefits 
experienced by others taking 
medication 
Sensitivity to drug benefits NO No data 
133 True clinical benefits True “wellness” YES  
134 True clinical benefits Perceived benefits YES  
135 True clinical benefits Sensitivity to drug benefits NO We do not include real drug data, and therefore 
assume sensitivity to drug effects to be constant 
over the duration of the simulation 
136 Sensitivity to drug benefits Perceived benefits YES  
137 Expectations of drug benefits Sensitivity to drug benefits NO We do not include real drug data, and therefore 
assume sensitivity to drug effects to be constant 
over the duration of the simulation 
138 Perceived benefits Expectations of drug benefits YES  
139 Perceived benefits Perceived “wellness” YES  
140 True “wellness” Perceived “wellness” YES  
141 Information received from health 
professionals 
Expectations of drug adverse 
effects 
NO No data 
142 Information received from health 
professionals 
Expectations of drug benefits NO No data 
143 Experience of taking similar / 
equivalent medication 
Expectations of drug adverse 
effects 
YES  
144 Experience of taking similar / 
equivalent medication 
Expectations of drug benefits YES  
145 Use of blister packs and / or other 
aids to organise medication 
Complexity and frequency of 
treatment regimen 
NO No data 
146 Complexity and frequency of 
treatment regimen 
Use of blister packs and / or other 
aids to organise medication 
NO No real drug data (and therefore regimen data) 
used in prototype 
147 Complexity and frequency of 
treatment regimen 
Level of interference with daily life NO No real drug data (and therefore regimen data) 
used in prototype 
148 Total number of drugs prescribed Complexity and frequency of 
treatment regimen 
NO Total number of drugs prescribed fixed at four in 
prototype 
149 Total number of drugs prescribed Concerns about potential long term 
effects 
NO Total number of drugs prescribed fixed at four in 
prototype 
150 Total number of drugs prescribed Adverse interactions with other 
drugs (POM and OTC) 
NO We assume no drugs other than those prescribed 
are available to the patient (and those interactions 
would be captured in the user-specified transition 
probabilities) 
151 Complexity and portability of 
format of delivery of drugs 
Stigma of taking medication in 
public (e.g. injections) 
NO No real drug data used in prototype 
152 Complexity and portability of 
format of delivery of drugs 
Level of interference with daily life NO No real drug data used in prototype 
153 Prioritisation of condition 
compared to comorbidities 
Adherence NO No data 
154 Seasonal and environmental 
factors 
Severity of condition NO We don’t use real condition progression data in the 
prototype, and so would be unable to translate this 
into the model 
155 Level of forgetfulness Adherence YES  
156 Age Level of forgetfulness NO No data – (Ardila, Ostrosky-Solis et al. 2000) looked 
at cognitive decline with age, but the nearest proxy 
they tested we could use would be “verbal 
memory”, but this does not show a significant 
reduction with age (or one that we could translate 
into the model in this context) 
157 Pattern of condition progression Adherence YES  
158 Time since onset Pattern of condition progression YES  
159 Desire to conceive Adherence NO We assume our population does not contain 
pregnant women (and therefore choose not to 
model a desire to conceive) 
160 Desire to conceive Pregnancy NO We assume our population does not contain 
pregnant women 
161 Caring responsibilities Adherence YES  
162 Living alone Caring responsibilities NO Not needed as user directly specifies caring 
responsibilities 
163 Perceived addictive qualities of 
medication 
Adherence NO Diabetes and asthma medications do not tend to be 
addictive in nature 
164 Addictive properties of medication Perceived addictive qualities of 
medication 
NO Diabetes and asthma medications do not tend to be 
addictive in nature 
 
Literature Cited 
Ardila, A., F. Ostrosky-Solis, M. Rosselli and C. Gómez (2000). "Age-Related Cognitive Decline During Normal Aging: The Complex Effect of Education." 
Archives of Clinical Neuropsychology 15(6): 495-513. 
Neuberger, J. (2000). "The educated patient: new challenges for the medical profession." Journal of Internal Medicine 247(1): 6-10. 
Osborn, C. Y., K. Cavanaugh, K. A. Wallston, S. Kripalani, T. A. Elasy, R. L. Rothman and R. O. White (2011). "Health Literacy Explains Racial Disparities in 
Diabetes Medication Adherence." Journal of Health Communication 16(sup3): 268-278. 
Sarkar, U., A. J. Karter, J. Y. Liu, N. E. Adler, R. Nguyen, A. López and D. Schillinger (2010). "The Literacy Divide: Health Literacy and the Use of an Internet-
Based Patient Portal in an Integrated Health System—Results from the Diabetes Study of Northern California (DISTANCE)." Journal of Health 
Communication 15(sup2): 183-196. 
Wald, H. S., C. E. Dube and D. C. Anthony (2007). "Untangling the Web—The impact of Internet use on health care and the physician–patient relationship." 
Patient Education and Counseling 68(3): 218-224. 
 
 
 
 
Appendix B 
Relationship 
# 
Influencing Factor 
 
(FROM) 
Factor Being Influenced 
(TO) 
Relationship in Literature Behavioural Rule Used in Model 
1 Affordability of medications to 
patient 
Adherence (Bezie, Molina et al. 2006) – 12 
out of 14 people in a higher 
socio-economic group were 
compliers, compared to 31 out 
of 80 in a lower socio-
economic group 
If socio-economic status = “low” 
then proposed action from 
affordability of medication is to 
adhere 39% of the time, else 
proposed action is to adhere 
86% of the time 
4 Level of education Health literacy (Schillinger, Barton et al. 2006) 
– health literacy increased 
moderately for those with up 
to A-Level education, and more 
significantly for those with up 
to university education 
Health literacy set to “low”, 
“medium” or “high” depending 
on whether level of education is 
“below A-Level”, “A-Level” or 
“university” 
8 Language barriers Frequency of interaction with 
health professionals 
(Derose and Baker 2000) – 
Latinos with fair and poor 
English proficiency reported 
around 22% fewer physician 
visits than non-Latinos whose 
native language was English, 
even after adjusting for other 
determinants of physician 
visits 
If primary language is not 
English, the probability of 
frequent contact with a 
physician is 22% lower 
9 Language barriers Health literacy (Schillinger, Barton et al. 2006) 
– health literacy moderately 
decreased for those for whom 
English is not primary language 
Reduce health literacy by one 
classification if English is not 
primary language (remain at 
“low” if health literacy is 
already “low”) 
10 Health literacy Frequency of research of (Murray, Lo et al. 2003) – 30% If health literacy = “low” then 
information on the internet of those with GCSE or A-Level 
equivalent education reported 
searching for health-related 
information on the internet.  
47% of those with an 
undergraduate degree 
reported searching for health-
related information on the 
internet.  57% of those with an 
advanced degree reported 
searching for information on 
the internet. 
30% probability of being 
influenced by information found 
on the internet else if health 
literacy = “medium” then 47% 
probability of being influenced 
by information found on the 
internet else 57% probability of 
being influenced by information 
found on the internet 
15 Preference to use non-drug 
alternatives (diet etc) 
Adherence (Chiu, Boonsawat et al. 2014) – 
around 12% of asthma patients 
agree or strongly agree that 
herbal medicines are safer 
than inhalers.  12.5% of those 
with low adherence agreed or 
strongly agreed with this. 
12% probability that person 
prefers alternative treatments.  
If they do, then the proposed 
action from this preference is to 
not adhere 12.5% of the time. 
17 Support in workplace / place of 
education to take medication 
Adherence (Nebiker-Pedrotti, Keller et al. 
2009) – discrimination in the 
workplace for those with 
diabetes ranges from 4% to 
15% in Switzerland 
 
John Marshall Law Review 
(McGrath 2004) – denial of 
access to medically needed 
treatment occurs in all types of 
employment.  Employers have 
denied or significantly 
restricted access to food, blood 
glucose testing and insulin. 
Probability of discrimination in 
the workplace is randomly true 
according to a uniform 
distribution with lower bound 
4% and upper bound 15%.  
Probability of proposed action 
from support in workplace 
being to adhere = 1 – 
probability of discrimination. 
18 Support in workplace / place of 
education to take medication 
Openness about condition (Ruston, Smith et al. 2013) – 
Private sector : 5/19 forced to 
disclose diabetes due to 
hypoglycaemic attack / 
sickness (received poor 
support), 6/19 reported full 
disclosure (received good 
support), 8/19 reported partial 
disclosure (only 1 of whom 
received any support).  Public / 
voluntary sector : 9/19 forced 
to disclose due to 
hypoglycaemic attack (received 
poor support), 4/19 reported 
full disclosure (3 of whom 
reported any support), 6/19 
reported partial disclosure (1 
of whom reported any 
support). 
If person works in public sector, 
there is a 75% probability that 
they will be open about their 
condition.  If person works in 
private sector then there is a 
12.5% probability that they will 
be open about their condition.  
If neither apply, then openness 
about condition is not modified 
by this influence. 
19 Openness about condition Adherence (Chiu, Boonsawat et al. 2014) – 
low adhering asthma patients 
more likely to report feeling 
uneasy about using inhaler in 
public (50.1%) compared to 
medium and high adhering 
patients (28.7%) 
If person currently taking at 
least one third of their 
prescribed medication, there is 
a 71.3% probability that they 
will be open about their 
condition.  If they are currently 
taking less than a third of their 
medication, there is a 49.9% 
that they will be open about 
their condition.  This may be 
overridden by the support they 
receive in the workplace 
(relationship #19) or their desire 
to feel “normal” (relationship 
#21).  If they are open about 
their condition, the proposed 
action from their openness will 
be to adhere, otherwise it will 
be to not adhere. 
20 Desire to feel “normal” by not 
having to take medication 
Adherence (Baiardini, Braido et al. 2006) – 
avoidance strategies for coping 
had negative correlation with 
taking medications correctly 
(coeff = -0.40). Inability to 
accept illness in 34.9% of 
patients and inability to accept 
limitations of illness (49.2%) 
may both impact on 
medication adherence. 
There is a 35% probability that 
the proposed action from a 
desire to feel “normal” is to not 
adhere. 
21 Desire to feel “normal” by not 
having to take medication 
Openness about condition (Partridge, van der Molen et al. 
2006) – 28% of asthma 
patients agreed that the 
thought of feeling different 
from other people was a 
negative aspect of asthma. 
There is a 72% probability that a 
person’s desire to feel “normal” 
will lead to them being open 
about their condition. 
25 Desire to be “in control” of self / 
condition 
Adherence (Polonsky, Fisher et al. 2005) – 
50.6% of diabetes patients 
believed that insulin therapy 
would restrict their lives 
 
(Mann, Ponieman et al. 2009) – 
48% of those with diabetes are 
poorly adherent when they 
have little confidence in their 
ability to control their 
diabetes, compared to 18% 
when they do have confidence 
There is a 49.4% probability that 
a person has confidence in their 
ability to control their 
condition.  If they do have this 
confidence, then the proposed 
action from desire to be in 
control is to not adhere 18% of 
the time.  If they don’t have this 
confidence, then the proposed 
action from desire to be in 
control is to not adhere 48% of 
the time. 
29 Life events Adherence (Helgeson, Escobar et al. 2010) 
–Adolescents with Type 1 
diabetes followed for 5 years : 
stressful life events led to 
poorer self-care behaviour 
 
(Bogner, Morales et al. 2012) – 
integrated care intervention to 
improve adherence to anti-
glycaemics and anti-
depressants for those suffering 
from depression was found 
after 12 weeks to have 
increased the % of good 
adherers from 35% to 65% 
(could view the “impact” of 
depression as 30% reduced 
adherence) 
User specifies frequency and 
duration of stressful events.  
When the person is 
experiencing a stressful event, 
the proposed action from this 
influence is to not adhere 30% 
of the time. 
31 Needle anxiety Adherence (Aronson 2012) – up to 94% of 
insulin users have symptoms of 
anxiety, stress or phobia - 33% 
dreaded injections, 22% had to 
mentally prepare themselves.  
Prescence of these symptoms 
strongly associated with less 
self-monitoring, fewer 
injections, poorer control 
There is a 33% probability that 
the person will suffer needle 
anxiety.  If they do, then the 
proposed action from this 
influence will be to not adhere. 
33 Gender Adherence (Kirkman, Rowan-Martin et al. 
2015) – males 14% more likely 
to adhere than females 
If person is female, proposed 
action from gender influence is 
to not adhere 14% of the time. 
34 Alcohol abuse, illicit drug use and 
smoking status 
Adherence (Baiardini, Braido et al. 2006) – 
use of alcohol has negative 
correlation with taking 
If alcohol use is high, then 
proposed action from this 
influence is to not adhere. 
medications correctly (coeff = -
0.30) 
37 Severity of condition Adherence (DiMatteo, Haskard et al. 2007) 
– there is a 22% higher risk of 
nonadherence among those 
who do not believe their 
condition is a threat because of 
its severity 
If person estimates their current 
combination of medication to 
provide them with above 
average (> 0.5) wellness, then 
the proposed action from the 
severity of condition is to not 
adhere 22% of the time. 
39 Time since onset Severity of condition No real condition progression 
data used, but mechanism for 
disease progression included in 
prototype 
User manually specifies daily 
probability of progression to 
different states of health 
40 Time since diagnosis Acceptance of diagnosis (Richardson, Adner et al. 2001) 
– people with insulin-
dependent diabetes with 
disease duration ranging from 
1-43 years had high degree of 
acceptance of condition (high 
Acceptance of Disability Scale 
Modified (ADM) Score) 
Grey et al (1997) – 1 year from 
diagnosis, children with 
diabetes tended to have stable 
psychosocial status and coping 
behaviours 
If time since diagnosis is one 
year or less, then the person 
does not accept their diagnosis.  
If time since diagnosis is greater 
than one year, then the person 
does accept their diagnosis. 
41 Acceptance of diagnosis Adherence (Gaude 2011) – 6% of asthma 
patients were non adherent 
due to anger about their 
condition 
If person accepts their 
diagnosis, then the proposed 
action from this influence is to 
adhere, otherwise the proposed 
action is to not adhere.  For 
those who do accept their 
diagnosis, there is a 6% 
probability that an anger about 
their condition will lead them to 
not accept their diagnosis. 
47 Time since diagnosis Adherence (Khattab, Khader et al. 2010) – 
80.7% of patients had poor 
glycemic control if they had 
diabetes for more than 7 years, 
compared to 50% for those 
with diabetes for 7 years or 
less 
If time since diagnosis is more 
than 7 years, then the proposed 
action from this influence will 
be to not adhere 80.7% of the 
time.  If time since diagnosis is 7 
years or less, then the proposed 
action from this influence will 
be to not adhere 50% of the 
time. 
60 Level of interference with daily 
life 
Adherence (Blaiss, Kaliner et al. 2009) – 
inconvenience was given as a 
reason for non adherence by 
3.7% of asthma patients 
 
(Mann, Ponieman et al. 2009) – 
43% are poorly adherent when 
diabetes significantly interferes 
with their social life 
3.7% probability that conditions 
interfere with daily life.  If 
conditions do interfere with 
daily life, the proposed action 
from this influence is to not 
adhere 43% of the time. 
61 Age Adherence (SAJITH, PANKAJ et al. 2014) – 
28.57% of 18-40 were low 
adherers, compared with 
17.65% of 41-60 and 27.66% of 
over 60 
If person aged 18-40, proposed 
action from this influence is to 
not adhere 29% of the time.  If 
person aged 41-60, proposed 
action from this influence is to 
not adhere 18% of the time.  If 
person aged over 60, proposed 
action from this influence is to 
not adhere 28% of the time. 
65 Age Deference (Kennelly and Bowling 2001) – 
patient group are all aged 56 
and over and displayed high 
If person aged 56 or over, 
deference increases by one 
classification (up to a maximum 
deference. of “high”). 
66 Deference Adherence (Bezie, Molina et al. 2006) – 
estimates based on figure 2.  
Of those Type 2 Diabetes 
patients with no regular 
follow-up, around 66% were 
non-compliers.  Of those with 
general practitioner follow-up 
around 44% were non-
compliers.  Of those with 
diabetologist follow-up around 
28% were non-compliers. 
User specifies level of deference 
to clinicians.  If level of 
deference is “low”, the 
proposed action from this 
influence is to not adhere 66% 
of the time.  If level of 
deference is “medium”, the 
proposed action from this 
influence is to not adhere 44% 
of the time.  Otherwise, the 
proposed action from this 
influence is to not adhere 28% 
of the time. 
68 Awareness of severity and / or 
nature of condition 
Adherence (Van Steenis, Driesenaar et al. 
2014) – asthma patient 
attitudes to inhaled 
corticosteroids (ICS).  44% 
were “Accepting” (high belief 
in necessity of treatment, low 
level of concern), 17% were 
“Ambivalent” (high belief in 
necessity of treatment, high 
level of concern), 6% were 
“Skeptical” (low belief in 
necessity of treatment, high 
level of concern) and 33% were 
“Indifferent” (low belief in 
necessity of treatment, low 
level of concern).  63.2% of 
those who were “Accepting”, 
40% of those who were 
“Ambivalent”, 80% of those 
User specifies level of 
understanding of necessity of 
treatment, and level of concern 
about condition.  Based on 
these choices, the person’s 
personality is determined as 
“Accepting” (high, low), 
“Ambivalent” (high, high), 
“Skeptical” (low, high) or 
“Indifferent” (low, low).  If 
personality is “Accepting”, the 
proposed action from this 
influence is to adhere 63.2% of 
the time.  If personality is 
“Ambivalent”, the proposed 
action from this influence is to 
adhere 40% of the time.  If 
personality is “Skeptical”, 
proposed action from this 
who were “Skeptical” and 
55.2% of those who were 
“Indifferent” were adherent 
(according to refills). 
influence is to adhere 80% of 
the time.  If personality is 
“Indifferent”, proposed action 
from this influence is to adhere 
55.2% of the time. 
74 Stigma of taking medication in 
public (e.g. injections) 
Adherence (Farsaei, Sabzghabaee et al. 
2015) – 15% of Type 2 Diabetes 
patients did not take statins 
because they don’t take 
medication when outside the 
home 
15% probability that the person 
doesn’t take their medication 
outside of the home.  If they 
don’t, then the proposed action 
from this influence is to not 
adhere. 
75 Influence of health professionals 
to promote adherence 
Adherence (Peláez, Lamontagne et al. 
2015) – 21.74% of patients 
received education / advice 
from a physician. 
 
(Meece 2014) – Type 2 
diabetes patients receiving 
advice were twice as likely to 
adhere 
21.74% probability that person 
is influenced by their physician.  
If they are, then the proposed 
action from this influence is to 
adhere.  If they don’t then the 
proposed action is to not 
adhere.  The physician’s 
influence may be overridden by 
relationship #94 or #105. 
76 Concerns about potential long 
term effects 
Adherence (Sundberg, Torén et al. 2010) – 
medication all the time was 
considered harmful by 48.2% 
of men with asthma and 35.3% 
of women with asthma 
(weighted average across 
population = 40.49%) 
 
(Van Steenis, Driesenaar et al. 
2014) – average probability of 
lower adherence for those with 
high concern (“Ambivalent” 
and “Skeptical” groups) was 
40.49% probability that person 
has concerns about the 
potential long term effects of 
medication.  If they do, then the 
proposed action from this 
influence is to not adhere 63.3% 
of the time. 
63.3% 
78 Difficulties obtaining timely 
repeat prescriptions 
Adherence (Chiu, Boonsawat et al. 2014) – 
25.8% of asthma patients felt it 
was inconvenient to get a new 
inhaler on time due to travel 
distance.  35.5% of such 
patients had low adherence. 
25.8% probability that person 
has difficulty getting timely 
repeat prescriptions.  If they do, 
then the proposed action from 
this influence is to not adhere 
35.5% of the time. 
82 Dislike of taking medications Adherence (Osman, Russell et al. 1993) – 
31% of patients reported 
disliking using daily medication 
 
(Gaude 2011) – 6% of people 
reported not adhering to 
medication due to a dislike of 
taking it. 
31% probability that person 
dislikes taking medications on a 
daily basis.  If they do, then 
proposed action from this 
influence is to not adhere 6% of 
the time. 
85 Perceived adverse effects Adherence Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
86 Perceived benefits Adherence Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
87 Perceived “wellness” Adherence Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
88 Influence of information found on 
the internet 
Adherence (Weaver Iii, Thompson et al. 
2009) – if a person searches for 
information on the internet 
they are 11.2% likely to not 
adhere 
If a person is influenced by 
information found on the 
internet, then the proposed 
action from this influence will 
be to not adhere 11.2% of the 
time. 
90 Influence of family, friends and 
carers (social connectivity) 
Adherence (SAJITH, PANKAJ et al. 2014) – 
family support was present 
with 35.24% of Type 2 Diabetes 
patients.  Of those with family 
support, 45.94% had high 
adherence, 35.13% had 
35.24% probability that person 
has family support.  If they do, 
then the proposed action from 
this influence is to not adhere 
18.92% of the time.  If they 
don’t, then the proposed action 
medium adherence and 
18.92% had low adherence.  Of 
those with no family support, 
35.29% had high adherence, 
39.7% had medium adherence 
and 25% had low adherence. 
from this influence is to not 
adhere 25% of the time. 
94 Relationship with / trust in health 
professionals 
Influence of health professionals to 
promote adherence 
(Whetten, Leserman et al. 
2006) – Mean level of trust in 
care providers (on scale from 3 
to 15) was 13.5 (standard 
deviation of 2.4).  Trust in care 
providers leads to patients 
being 1.15 times more likely to 
use their medication. 
Level of trust in health 
professionals selected randomly 
on normal distribution with 
mean of 13.5 and standard 
deviation of 2.4.  If this trust 
level >= 7.5, then the person is 
influenced by their physician. 
95 Relationship with / trust in health 
professionals 
Frequency of research of 
information on the internet 
(Murray, Lo et al. 2003) – 71% 
of patients reported an 
excellent / very good level of 
care from their physician, 
compared to 21% good and 8% 
fair / poor.  Of those who rated 
their level of care as excellent / 
very good or good, 32% 
searched for health 
information on the internet.  
Of those who rated their level 
of care as fair / poor, 40% 
searched for health 
information on the internet.  
If trust in health professionals 
(calculated in relationship #94) 
>= 7.5, then there is a 32% 
probability of being influenced 
by information found on the 
internet, otherwise there is a 
40% probability of being 
influenced by information found 
on the internet. 
98 Frequency of research of 
information on the internet 
Influence of information found on 
the internet 
(Incorporated in relationships 
#10, #88, #95) 
(Incorporated in relationships 
#10, #88, #95) 
105 Frequency of interaction with 
health professionals 
Influence of health professionals to 
promote adherence 
(Bezie, Molina et al. 2006) – 
16.03% of Type 2 Diabetes 
have regular appointments 
There is a 16.03% probability of 
frequent contact with health 
professionals (if primary 
with a medical practitioner 
(Hospital doctor, GP or nurse). 
 
(Corsico, Cazzoletti et al. 2007) 
– If patient has regular 
appointments and current 
adherence is low/medium then 
increased adherence is 3.32 
times more likely 
If patient has regular 
appointments and current 
adherence is high 
adherence at the continued 
level is 1.23 times more likely. 
language is English).  If there is 
frequent contact, then person is 
influenced by their physician 
(overriding relationship #75). 
106 Reluctance to consult with 
professionals for fear of “wasting 
their time” 
Frequency of interaction with 
health professionals 
(Nichols 1983) – 90/1140 
(7.89%) of women reluctant to 
visit the doctor due to 
believing they are a nuisance.   
7.89% probability that the 
person will be reluctant to 
consult with doctor.  If this is 
the case, then patient does not 
have frequent contact with 
health professionals (overriding 
calculations in relationship #8 
and #105) 
119 Perceived adverse effects Concerns about potential long 
term effects 
Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
120 Perceived adverse effects Expectations of drug adverse 
effects 
Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
121 Perceived adverse effects Perceived “wellness” Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
122 Sensitivity to drug adverse effects Perceived adverse effects Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
123 True adverse effects Perceived adverse effects Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
125 True adverse effects True “wellness” Captured by Reinforcement Captured by Reinforcement 
Learning algorithm Learning algorithm 
133 True clinical benefits True “wellness” Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
134 True clinical benefits Perceived benefits Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
136 Sensitivity to drug benefits Perceived benefits Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
138 Perceived benefits Expectations of drug benefits Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
139 Perceived benefits Perceived “wellness” Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
140 True “wellness” Perceived “wellness” Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
143 Experience of taking similar / 
equivalent medication 
Expectations of drug adverse 
effects 
Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
144 Experience of taking similar / 
equivalent medication 
Expectations of drug benefits Captured by Reinforcement 
Learning algorithm 
Captured by Reinforcement 
Learning algorithm 
155 Level of forgetfulness Adherence (Blaiss, Kaliner et al. 2009) – 
7.3% of reported asthma 
patients fail to take medication 
because they forget (5.2% of 
asthma patients reported the 
same). 
 
(Gaude 2011) – 10% of asthma 
patients said they fail to take 
medication because they 
forget. 
Level of forgetfulness for the 
person is randomly selected 
from uniform distribution with 
lower bound 0.052 and upper 
bound 0.1.  The proposed action 
from this influence is to not 
adhere for the percentage of 
time represented by the level of 
forgetfulness (so if level of 
forgetfulness is 0.1, the 
proposed action will be to not 
adhere 10% of the time). 
157 Pattern of condition progression Adherence User specified in prototype User specified in prototype 
158 Time since onset Pattern of condition progression User specified in prototype User specified in prototype 
161 Caring responsibilities Adherence (Pourghaznein, Ghaffari et al. 
2013) – there is a negative 
User specifies level of caring 
responsibility.  If level = “none”, 
correlation between 
medication adherence and the 
number of children a person 
has. 
 
(Barr, Somers et al. 2002) – 7% 
of older women with asthma 
care for an ill spouse.  Of those 
that care for ill spouse 1-8 
hours per week, 60% are 
adherent.  Of those that care 
for ill spouse 9-20 hours per 
week, 42% are adherent.  Of 
those that care for ill spouse >= 
21 hours per week, 37% are 
adherent. 
then proposed action from this 
influence is to adhere.  If level = 
“low”, then proposed action 
from this influence is to not 
adhere 40% of the time.  If level 
= “medium”, then proposed 
action from this influence is to 
not adhere 58% of the time.  If 
level = “high”, then proposed 
action from this influence is to 
not adhere 63% of the time. 
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